Skandinaviska Enskilda Banken AB publ Has $3.86 Million Holdings in Medpace Holdings, Inc. $MEDP

Skandinaviska Enskilda Banken AB publ trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 87.3% in the 3rd quarter, Holdings Channel reports. The fund owned 7,500 shares of the company’s stock after selling 51,497 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Medpace were worth $3,858,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Fifth Third Wealth Advisors LLC raised its stake in Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of Medpace by 2.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares during the period. Portside Wealth Group LLC raised its position in shares of Medpace by 2.5% during the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after buying an additional 27 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of Medpace by 35.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares during the last quarter. Finally, M&T Bank Corp lifted its stake in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Medpace stock opened at $453.77 on Friday. The business has a 50 day simple moving average of $556.01 and a 200 day simple moving average of $537.96. The company has a market capitalization of $12.88 billion, a PE ratio of 29.66, a price-to-earnings-growth ratio of 2.14 and a beta of 1.42. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period in the prior year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This trade represents a 7.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 201,745 shares of company stock valued at $122,369,738 over the last three months. 20.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MEDP. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Mizuho set a $582.00 price objective on Medpace in a research report on Wednesday, February 11th. BMO Capital Markets restated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a research report on Wednesday. Finally, Leerink Partners lowered their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $483.45.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.